Elan Pharmaceuticals (ELN) Seeks Fast Sale of Drug Delivery Unit According to Sources

Elan Pharmaceuticals (ELN) Seeks Fast Sale of Drug Delivery Unit According to Sources
8/12/2008

LONDON/NEW YORK, Aug 12 (Reuters) - Ireland's Elan Corp has received first-round bids for its drug delivery unit and is hoping for a quick sale of the business, which may fetch as much as $1.3-1.4 billion, according to people familiar with the matter.

 

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.